Communication to the Editor
Metabolite profiling of recombinant CHO cells: Designing tailored feeding regimes that enhance recombinant antibody production
Article first published online: 10 AUG 2011
DOI: 10.1002/bit.23269
Copyright © 2011 Wiley Periodicals, Inc.
Additional Information
How to Cite
Sellick, C. A., Croxford, A. S., Maqsood, A. R., Stephens, G., Westerhoff, H. V., Goodacre, R. and Dickson, A. J. (2011), Metabolite profiling of recombinant CHO cells: Designing tailored feeding regimes that enhance recombinant antibody production. Biotechnol. Bioeng., 108: 3025–3031. doi: 10.1002/bit.23269
Publication History
- Issue published online: 13 OCT 2011
- Article first published online: 10 AUG 2011
- Accepted manuscript online: 18 JUL 2011 08:28AM EST
- Manuscript Accepted: 5 JUL 2011
- Manuscript Revised: 2 JUN 2011
- Manuscript Received: 21 MAR 2011
Funded by
- BBSRC
- EPSRC
- Bioprocessing Research Industry Club (BRIC)
Keywords:
- metabolite profiling;
- antibody;
- glutamine synthetase;
- CHO cells;
- bioprocessing;
- GC-MS
Abstract
Chinese hamster ovary (CHO) cells are the primary platform for commercial expression of recombinant therapeutic proteins. Obtaining maximum production from the expression platform requires optimal cell culture medium (and associated nutrient feeds). We have used metabolite profiling to define the balance of intracellular and extracellular metabolites during the production process of a CHO cell line expressing a recombinant IgG4 antibody. Using this metabolite profiling approach, it was possible to identify nutrient limitations, which acted as bottlenecks for antibody production, and subsequently develop a simple feeding regime to relieve these metabolic bottlenecks. This metabolite profiling-based strategy was used to design a targeted, low cost nutrient feed that increased cell biomass by 35% and doubled the antibody titer. This approach, with the potential for utilization in non-specialized laboratories, can be applied universally to the optimization of production of commercially important biopharmaceuticals. Biotechnol. Bioeng. 2011;108: 3025–3031. © 2011 Wiley Periodicals, Inc.
1097-0290/asset/BIT_left.gif?v=1&s=5f6054ce9ff7b0421e44e8e4e33966356f37b71c)
